comparing treatment efficacy of high versus low dose iodine ablation in intermediate risk thyroid cancer patients referring to thyroid clinic of nuclear medicine department of GHAEM hospital in the years 1392 to 1395

Treatment efficacy of high versus low dose post thyroidectomy iodine ablation in intermediate risk patients with differentiated thyroid cancer , refering to thyroid clinic of nuclear medicine department of GHAEM hospital in the years 1392 to 1395.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016011626038N1

Enrollment

150

Registered

2016-05-08

Start date

2014-12-31

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant neoplasm of thyroid gland. Malignant neoplasm of thyroid gland

Interventions

Intervention 1: administration of 150 mci of I131. Intervention 2: administration of 30mci of I131.

Treatment - Drugs

administration of 150 mci of I131

administration of 30mci of I131.

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Inclusion:age more than 18 years/ diagnosis of DTC by a reliable pathology/history of total thyroidectomy / recieved no other treatments such as radiotherapy and/or iodine ablation after surgery/ no evidence of distant metastasis at initial evaluation/ categorizing in either of these groups: age more than 45 yeras: T1N1b,T2N0,T2N1a,T3N0; age less than 45 years: T21a,T2N1b,T3N0,T3N1a Exclusion: incomplete thyroid surgery; first serum Throglobulin level more than 60 ng/dl; distant metastasis/ T4

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Response to treatment categorize as 3 groups: excellent response, acceptable response and incomplete response. Timepoint: 1 year after treament. Method of measurement: according to patients lab test in the off drug status, such as thyroglobulin, anti thyroglobulin , neck ultrasonography and diagostic whole body iodine scan,if needed.	—

Secondary

Measure	Time frame
Serum thyroglobulin. Timepoint: 1 year after treatment. Method of measurement: lab data.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Athena Aghaee

Mashhad University of Medical Sciences

aghaeea911@mums.ac.ir+98 51 3840 9611

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026